Skip to main content

Omnicell, Inc.

corporate_fare Company Profile

Omnicell, Inc.

OMCL·NASDAQ·Technology·CIK 0000926326

Omnicell is a healthcare technology provider that focuses on autonomous medication management. The company aims to address challenges in medication management and support clinicians in healthcare. Omnicell helps customers develop cost-effective medication management strategies, enabling pharmacists and nurses to prioritize patient care over administrative tasks. This approach seeks to improve clinical, operational, and financial outcomes across various care settings. Omnicell's offerings include a medication management infrastructure with storage and dispensing automation, supported by an intelligence ecosystem. These solutions form the basis for customers to achieve the Autonomous Pharmacy, an industry vision aimed at improving operational efficiencies and targeting zero-error medication management, along with five other outcomes outlined in the Autonomous Pharmacy framework. In 2024, the United States spent $806 billion on prescription drugs, representing a 10.2% increase from 2023. The company identifies significant challenges in pharmacy practice, such as budget constraints and workforce shortages. Specifically, 88% of hospitals report technician deficits, and 92% lack sufficient sterile compounding expertise. Health systems also face increased liability from drug diversion, with a 61% increase in the average number of investigations per hospital since the beginning of 2023. Omnicell believes these challenges will drive demand for automation, visibility, insights, and improved medication management outcomes, which their solutions are designed to provide.

Omnicell, Inc. (NASDAQ:OMCL) is a publicly traded company in the Technology sector. Wiseek has independently scored 11 items for OMCL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-30, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for OMCL spans 8-K, 10-Q, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Omnicell Crushes Q2 EPS Estimates, Raises EBITDA Outlook on Tariff Refund Boost
  • Omnicell Q2 Revenue Reaches $312M, Full-Year Profit Outlook Raised
  • Omnicell Guides Q3 Revenue to $301M-$307M, Setting the Bar for the Quarter
  • Omnicell Appoints Nnamdi Njoku as President; CEO Randall Lipps Shifts Focus
  • Omnicell Stockholders Approve 1.6 Million Share Increase for Equity Incentive Plan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.18B
Net Income
$2.05M
Diluted EPS
$0.04
Op. Cash Flow
$127.3M
Free Cash Flow
$86.89M
Gross Profit
$503.44M
Operating Income
$5.16M
Cash & Equivalents
$196.52M
Debt / Equity
0.00×
Net Margin
0.2%
Shares Outstanding
45.03M sh
Source: 10-K · filed 2026-02-26 · accession 0000926326-26-000006

Short Interest & Short Volume

5.48 days to cover

FINRA reported short interest of 3,291,305 shares in OMCL as of the September 15, 2026 settlement, a 0.1% decrease from the prior period — about 5.5 days to cover at its recent average daily volume. On October 2, 2026, 61.5% of OMCL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,291,305 shares as of September 15, 2026
Change vs prior period▼ 0.1%
Days to cover5.48 at avg daily volume of 600,197
Daily short volume (FINRA facilities)61.5% of 106,520 shares on October 2, 2026
5-day average short volume65.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$33.6
52-week range · as of 2026-07-30 $28.51 – $55
Market cap
$1.53B
Volume
344.5K (0.6× avg)
3-mo avg 580K
Live data · 2026-10-05 03:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OMCL - Latest Insights

OMCL
Jul 30, 2026, 6:53 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.40
Real-time Price: $33.60 info
Change: -$7.80 (-19%) info
Market Cap: $1.533B info
OMCL
Jul 30, 2026, 6:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.40
Real-time Price: $33.60 info
Change: -$7.80 (-19%) info
Market Cap: $1.533B info
OMCL
Jul 30, 2026, 6:34 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $41.40
Real-time Price: $33.60 info
Change: -$7.80 (-19%) info
Market Cap: $1.533B info
OMCL
Jul 01, 2026, 8:27 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.66
Real-time Price: $33.60 info
Change: -$8.06 (-19%) info
Market Cap: $1.533B info
OMCL
May 26, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.10
Real-time Price: $33.60 info
Change: -$10.50 (-24%) info
Market Cap: $1.533B info
OMCL
May 06, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $43.76
Real-time Price: $33.60 info
Change: -$10.16 (-23%) info
Market Cap: $1.533B info
OMCL
Apr 28, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.49
Real-time Price: $33.60 info
Change: -$5.89 (-15%) info
Market Cap: $1.533B info
OMCL
Apr 13, 2026, 4:16 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $35.01
Real-time Price: $33.60 info
Change: -$1.41 (-4%) info
Market Cap: $1.533B info
OMCL
Apr 02, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $34.15
Real-time Price: $33.60 info
Change: -$0.550 (-2%) info
Market Cap: $1.533B info
OMCL
Feb 26, 2026, 4:07 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $41.93
Real-time Price: $33.60 info
Change: -$8.33 (-20%) info
Market Cap: $1.533B info
OMCL
Feb 05, 2026, 6:32 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.63
Real-time Price: $33.60 info
Change: -$14.03 (-29%) info
Market Cap: $1.533B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets